Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRB2 | P07550 | 1/20 | 0.62 |
| ▸ | STAT3 | P40763 | 2/20 | 0.54 |
| ▸ | TOP2A | P11388 | 6/20 | 0.49 |
| ▸ | TOP2B | Q02880 | 6/20 | 0.49 |
| ▸ | KCNH2 | Q12809 | 3/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.43 |
| ▸ | HPGD | P15428 | 2/20 | 0.43 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2844967 | 0.92 | ADRB2 (0.68) | ADRB2STAT3TOP2ATOP2BKCNH2 | |
| SCHEMBL29492858 | 0.92 | ADRB2 (0.68) | ADRB2STAT3TOP2ATOP2BKCNH2 | |
| SCHEMBL143605 | 0.90 | ADRB2 (0.64) | ADRB2STAT3TOP2ATOP2BKCNH2 | |
| SCHEMBL7575069 | 0.88 | ADRB2 (0.61) | ADRB2STAT3TOP2ATOP2BKCNH2 | |
| SCHEMBL9188190 | 0.88 | ADRB2 (0.61) | ADRB2STAT3TOP2ATOP2BKCNH2 | |
| SCHEMBL10627001 | 0.88 | ADRB2 (0.66) | ADRB2STAT3TOP2ATOP2BKCNH2 | |
| SCHEMBL114727 | 0.87 | ADRB2 (0.61) | ADRB2STAT3TOP2ATOP2BKCNH2 | |
| SCHEMBL8735574 | 0.87 | ADRB2 (0.61) | ADRB2STAT3TOP2ATOP2BKCNH2 | |
| SCHEMBL1989474 | 0.87 | ADRB2 (0.61) | ADRB2STAT3TOP2ATOP2BKCNH2 | |
| SCHEMBL29391687 | 0.87 | ADRB2 (0.61) | ADRB2STAT3TOP2ATOP2BKCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 46 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-112641773-A | Composition containing heterocyclic compound and use thereof | 黄泳华 | 2021-04-13 | — | — | CN | claimed |
| CN-111514125-B | Composition containing quinolone compound and edetic acid compound | 中山万汉制药有限公司 | 2021-03-23 | — | — | CN | claimed |
| CN-111514125-A | Composition containing quinolone compound and edetic acid compound | 中山万汉制药有限公司 | 2020-08-11 | — | — | CN | claimed |
| CN-111150734-A | Compositions containing mixtures of quinolinone derivatives and uses thereof | 黄泳华 | 2020-05-15 | — | — | CN | claimed |
| CN-117658911-A | Preparation method of gative ester | 黑龙江珍宝岛药业股份有限公司 | 2024-03-08 | — | — | CN | disclosed |
| CN-112641773-A | Composition containing heterocyclic compound and use thereof | 黄泳华 | 2021-04-13 | — | — | CN | disclosed |
| CN-111514125-B | Composition containing quinolone compound and edetic acid compound | 中山万汉制药有限公司 | 2021-03-23 | — | — | CN | disclosed |
| CN-111514125-A | Composition containing quinolone compound and edetic acid compound | 中山万汉制药有限公司 | 2020-08-11 | — | — | CN | disclosed |
| CN-111150734-A | Compositions containing mixtures of quinolinone derivatives and uses thereof | 黄泳华 | 2020-05-15 | — | — | CN | disclosed |
| CN-110878047-A | Gatifloxacin carboxylic acid and its synthesis method | 怀化学院 | 2020-03-13 | — | — | CN | disclosed |
| EP-2013182-B1 | AMINOQUINOLONES AS GSK-3 INHIBITORS | KYORIN SEIYAKU KK (JP) | 2013-09-04 | — | — | EP | disclosed |
| EP-2013182-B1 | AMINOQUINOLONES AS GSK-3 INHIBITORS | KYORIN SEIYAKU KK (JP) | 2013-09-04 | — | — | EP | disclosed |
| WO-2008062379-A2 | 4- (2-OXO-OXAZOLIDIN-3YL)-PHENOXYMETHYLE DERIVATIVEAS AS ANTIBACTERIALS | ACTELION PHARMACEUTICALS LTD (CH) | 2008-05-29 | — | — | WO | disclosed |
| US-20070254866-A1 | Aminoquinolones as GSK-3 inhibitors | KYORIN PHARMACEUTICAL CO., LTD. (JP) | 2007-11-01 | — | — | US | disclosed |
| US-20070254866-A1 | Aminoquinolones as GSK-3 inhibitors | KYORIN PHARMACEUTICAL CO., LTD. (JP) | 2007-11-01 | — | — | US | disclosed |
| US-20070254866-A1 | Aminoquinolones as GSK-3 inhibitors | KYORIN PHARMACEUTICAL CO., LTD. (JP) | 2007-11-01 | — | — | US | disclosed |
| WO-2007106537-A2 | AMINOQUINOLONES AS GSK-3 INHIBITORS | ACTIVX BIOSCIENCES, INC. (US) | 2007-09-20 | — | — | WO | disclosed |
| US-20070219231-A1 | Quinolonecarboxylic acid compounds, preparation methods and pharmaceutical uses thereof | XINCHANG PHARMACEUTICAL FACTORY, ZHEJIANG MEDICINE CO. LTD. (CN) | 2007-09-20 | — | — | US | disclosed |
| EP-1767536-A1 | QUINOLONE CARBOXYLIC ACID DERIVATIVES, THEREOF PREPARATION AND USAGE | Institute of Medicinal Biotechnology, Chinese Acadamy of Medical Sciences (CN) | 2007-03-28 | — | — | EP | disclosed |
| WO-2007017828-A2 | OXAZOLIDINONE-QUINOLONE HYBRIDS AS ANTIBACTERIAL COMPOUNDS | ACTELION PHARMACEUTICALS LTD (CH) | 2007-02-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070254866-A1 | Aminoquinolones as GSK-3 inhibitors | GSK3B, GSK3A, GSKIP | ADRB2 2944/4885STAT3 115/4885TOP2A 205/4885 |
| US-20070219231-A1 | Quinolonecarboxylic acid compounds, preparation methods and pharmaceutical uses thereof | NQO2, ABCG2, DHX15 | ADRB2 3671/4885STAT3 3550/4885TOP2A 256/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.